Sustainable releasing / Microspherical antigen formulation

Based on the mechanisms of action, adjuvants can be classified as immunostimulants and delivery systems. Adjuvants act as delivery systems by binding closely to antigens and sustainably releasing them, thereby prolonging the bioavailability of the antigen and enhancing antigen presentation. This approach can also help reduce the amount of antigen and adjuvant needed, thereby minimizing potential adverse effects and waste. Sustainable release/microspherical antigen formulations mainly include water-in-oil emulsion formulation (W/O), oil-in-water emulsion formulation (O/W), antigen encapsulation formulation, core-shell structures for sustainable release, and metal nanoparticle-based formulations.

Product Name	Catalog	Unit Size	Price
Mannide monooleate	CDAD24-006-T	10 mL, 25 mL	INQUIRY
Mineral oil	CDAD24-007-T	10 mL, 50 mL, 75 mL	INQUIRY
Monomycoloyl glycerol-1 (MMG-1) adjuvant	CDAD24-033-T	5 mg, 25 mg	INQUIRY
Mn2+-assisted nanofiber hydrogel adjuvant	CDAD24-143-T	2 mL	INQUIRY
NTA (Ni)-based liposome adjuvant	CDAD24-036-T	2 mL	INQUIRY
Peanut oil	CDAD24-005-T	50 mL	INQUIRY
PLGA poly(lactic-co-glycolic) acid)	CDAD24-103-T	500 mg	INQUIRY
Poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide)	CDAD24-102-T	0.1 g	INQUIRY
Poly(I:C) (Polyinosinic-Polycytidylic) Synthetic	CDAD24-106-T	10 mg, 50 mg	INQUIRY
Poly(lactide-co-glycolide) star, glucose core, hydroxyl terminated vaccine adjuvant	CDAD24-104-T	0.1 g	INQUIRY
PtdIns-(3,4,5)-P3(1,2-dihexanoyl) ammonium	CDAD24-041-T	50 mg, 100 mg, 250 mg	INQUIRY
Sorbitan Trioleate (Span 85)	CDAD24-010-T	500 g	INQUIRY
Synthetic PLGA poly(lactic-co-glycolic) acid)	CDAD24-105-T	1 g	INQUIRY
Trehalose 6,6'-Dibehenate (TDB)	CDAD24-031-T	5 mg, 25 mg	INQUIRY
Vaxfectin	CDAD24-037-T	1 mg, 5 mg, 10 mg	INQUIRY
VC1052	CDAD24-040-T	50 mg, 100 mg, 250 mg	INQUIRY

Previous 1 2 Next